VIA
NEO icon

Vident Investment Advisory’s NeoGenomics NEO Stock Holding History

Vident Investment Advisory’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,167
Closed -$229K – 1299
2023
Q1 		$229K Buy
13,167
+1,802
+16% +$25.7K 0.01% 1051
2022
Q4 		$105K Sell
11,365
-1,094
-9% -$10.2K ﹤0.01% 1103
2022
Q3 		$102K Buy
12,459
+1,115
+10% +$11.1K ﹤0.01% 1055
2022
Q2 		$91K Buy
+11,344
New +$108K ﹤0.01% 1204
2021
Q3 		– Sell
-4,704
Closed -$212K – 1205
2021
Q2 		$212K Buy
+4,704
New +$208K 0.01% 1033

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Investment Advisory's NEO Position: Q2 2023 in Review

Vident Investment Advisory sold out of NeoGenomics (NEO) in Q2 2023, closing a stake of 13,167 shares — an estimated $229K sold.

Vident Investment Advisory first reported a position in NEO in Q2 2021 and held it in 5 quarters. The position peaked at $229K in Q1 2023. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2023.

  • Vident Investment Advisory reported no remaining NeoGenomics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 13,167 NeoGenomics shares in Q2 2023, an estimated $229K.
  • Vident Investment Advisory first reported a position in NeoGenomics in Q2 2021 and held it in 5 quarters.
  • Vident Investment Advisory's NeoGenomics position peaked at $229K in Q1 2023.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.